Next quarter’s earnings estimate for 9969 is HK$0.09 with a range of HK$0.09 to HK$0.09. The previous quarter’s EPS was ―. 9969 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 41.32% of the time in the same period. In the last calendar year 9969 has Outperformed its overall industry.

9969 Sales Forecast

Next quarter’s sales forecast for 9969 is HK$415.41M with a range of HK$415.41M to HK$415.41M. The previous quarter’s sales results were ―. 9969 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 55.19% of the time in the same period. In the last calendar year 9969 has Underperformed its overall industry.

Detailed List of Analyst Forecasts

Chen Chen

UBS

HK$11.60

Buy

128.35%

Upside

Reiterated

11/14/23

InnoCare Pharma Limited (9969:HK) (INCPF) PT Lowered to HK$11.60 at UBSUBS analyst Chen Chen lowered the price target on InnoCare Pharma Limited (9969:HK) (OTC: INCPF) to HK$11.60 (from HK$12.60) while maintaining a Buy rating.

Jill Wu

CMB International Securities

HK$9.07

Buy

78.54%

Upside

Reiterated

08/31/23

We expect orelabrutinib to add MZL indication to the NRDL in early 2024. The Ph3 study of orelabrutinib in 1L CLL/SLL has fully enrolled with NDA filing expected in 2024, and a Ph3 study in DLBCL-MCD is ongoing in China. InnoCare completed the patient enrolment in 1H23 for the Ph2 registrational trial of orelabrutinib in r/r MCL with the BLA expected in mid- 2024. The Company is actively looking for an overseas partner for orelabrutinib. ICP-248 (BCL-2) is in Ph1 dose escalation stage with promising early signals. In 3 patients, 2 reached CR and uMRD, suggesting the potential of ICP-248 to combo orelabrutinib for 1L CLL/SLL, with the US IND filing expected by end-2023. The bridging study of tafasitamab in mainland China has fully enrolled the 52 patients. With data release in the next 6 months, the Company expects to file the BLA of tafasitamab in mainland China in 2Q24.

Best Analysts Covering InnoCare Pharma Ltd.

Which Analyst Should I Follow If I Want to Buy HK:9969 and Sell After:

1 Month

Chen ChenUBS

Success Rate

0/1 ratings generated profit

Average Return

-5.50%

reiterated a buy rating 6 months ago

Copying Chen Chen's trades and holding each position for 1 Month would result in 0.00% of your transactions generating a profit, with an average return of -5.50% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Jill WuCMB International Securities

Success Rate

0/1 ratings generated profit

Average Return

-0.70%

reiterated a buy rating 9 months ago

Copying Jill Wu's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -0.70% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Chen ChenUBS

Success Rate

0/1 ratings generated profit

Average Return

-22.30%

reiterated a buy rating 6 months ago

Copying Chen Chen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -22.30% per trade.

2 Years

Chen ChenUBS

Success Rate

0/1 ratings generated profit

Average Return

-22.30%

reiterated a buy rating 6 months ago

Copying Chen Chen's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -22.30% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

9969 Analyst Recommendation Trends

Rating

Mar 23

May 23

Aug 23

Nov 23

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 9969 has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 9969 average Analyst price target in the past 3 months is ―.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

9969 Stock Forecast FAQ

What is HK:9969’s average 12-month price target, according to analysts?

Currently, no data Available

What is HK:9969’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for HK:9969, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is InnoCare Pharma Ltd. a Buy, Sell or Hold?

Currently, no data Available

What is InnoCare Pharma Ltd.’s share price target?

Currently, no data Available

What do analysts say about InnoCare Pharma Ltd.?

Not enough analysts have published a price target to provide an average price target.

How can I buy shares of InnoCare Pharma Ltd.?

To buy shares of HK:9969, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

InnoCare Pharma Ltd. (9969) Stock Forecast & Price Target

9969 Analyst Ratings

9969 Stock 12 Month Forecast

9969 Financial Forecast

9969 Earnings Forecast

9969 Sales Forecast

Detailed List of Analyst Forecasts​

Best Analysts Covering InnoCare Pharma Ltd.

9969 Analyst Recommendation Trends

9969 Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts